Program
FXS6837
A development code. Also written as “FXS6837 Capsule”, “FXS6837 Dose 1” and “FXS6837 Dose 2”.
In Fosun Pharma's pipeline, CFB
. Its studies are mostly in Hemoglobinuria, Paroxysmal, led by Fosun Pharma.
Furthest: phase 3, since Jul 22, 20264 company-led studies, 4 open or runningNext primary completion: Sep 12, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Fosun Pharma | 44 open or running | phase 3since Jul 22, 2026 | Mar 15, 2026 | Sep 12, 2027phase 2 · NCT07502638 |
- Named in Fosun Pharma’s own pipeline as
FXS6837 (CFB)
, phase 2, as of Sep 21, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 15, 2026First study: phase 2 study in IgANFirst studyNCT07502638 · 60 planned · China
- Jul 22, 2026Phase 3 study in Hemoglobinuria, ParoxysmalPhase 3 reachedNCT07747090 · 90 planned · China
- Aug 2, 2026Phase 2 study in Primary IgANNCT07750665 · 60 planned · China
- Oct 13, 2026Phase 3 study in Hemoglobinuria, ParoxysmalNCT07914894 · 20 planned · China
Ahead
- Sep 12, 2027Primary completion: phase 2 study in IgANNCT07502638
- May 5, 2028Primary completion: phase 3 study in Hemoglobinuria, ParoxysmalNCT07747090
- May 17, 2028Primary completion: phase 3 study in Hemoglobinuria, ParoxysmalNCT07914894
- Nov 13, 2029Primary completion: phase 2 study in Primary IgANNCT07750665
TargetBeta
“CFB”the company's pipeline, read by Claude · source
Other programs on CFB
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07914894Hemoglobinuria, Paroxysmal · China | 3 | Not yet recruiting | May 17, 2028 | 20 |
| NCT07750665Primary IgAN · China | 2 | Not yet recruiting | Nov 13, 2029 | 60 |
| NCT07747090Hemoglobinuria, Paroxysmal · China | 3 | Not yet recruiting | May 5, 2028 | 90 |
| NCT07502638IgAN · China | 2 | Not yet recruiting | Sep 12, 2027 | 60 |
How it is read
Names in the registry
- “FXS6837 Capsule”, 3 entries
- “FXS6837 Dose 1”, 1 entry
- “FXS6837 Dose 2”, 1 entry
Codes read as this program: FXS6837.
Conditions, from the studies’ own filings
- Hemoglobinuria, Paroxysmal, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.